

Nebulised Taurolidine

The Leeds Method of Management. April, 2008. Nebulised Taurolidine [online]. Leeds Regional Adult and Paediatric Cystic Fibrosis Units, St James's University Hospital, Leeds, UK. Available from <http://www.cysticfibrosismedicine.com>

Introduction

Taurolidine is an unlicensed product available as an intraperitoneal lavage (Taurolin®). It acts as an antibiotic and an anti-endotoxin with a broad spectrum of activity against Gram negative and positive bacteria and fungi. Taurolidine is active in vitro against *P. aeruginosa* and *Burkholderia Cepacia Complex* (Bcc) (Perry *et al*, 2002) but a four week randomised, double-blind, placebo controlled trial of 4mls nebulised taurolidine solution 2% versus saline solution in 20 adult patients with CF showed no in-vivo anti-Bcc activity (Ledson *et al*, 2002). Successful Bcc eradication has been reported in a non-CF patient (Ledson *et al*, 2000). Taurolidine may cause bronchospasm, cough or a mild 'burning' sensation in the throat. An initial test dose should be given. Care is advised in renal insufficiency.

Key points

- Taurolidine is active in vitro against *P. aeruginosa* and Bcc
- Taurolidine is an unlicensed product

References

Ledson MJ, Cowperthwaite C, Walshaw MJ, *et al*. Nebulised taurolidine and cepacia bronchiectasis. *Thorax* 2000; 55: 91-92.

Ledson MJ, Gallagher MJ, Robinson M, *et al*. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with *Burkholderia cepacia*. *J Aerosol Med.* 2002;15(1):51-7.

Perry JD, Riley G, Johnston S, *et al*. Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis. *J Heart Lung Transplant* 2002; 21: 1230-1231.